Research Advances of Immunotherapy of Exosome PD-L1
in Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2022.102.33
- Author:
Na WANG
1
;
Xia SONG
2
Author Information
1. The Second Clinical Medical College of Shanxi Medical University, Taiyuan 030000, China.
2. The Second Department of Respiratory, Shanxi Provincial Cancer Hospital, Taiyuan 030000, China.
- Publication Type:Review
- Keywords:
Exosome;
Immunotherapy;
Lung neoplasms;
PD-L1
- MeSH:
B7-H1 Antigen;
CTLA-4 Antigen;
Carcinoma, Non-Small-Cell Lung/pathology*;
Exosomes/pathology*;
Humans;
Immune Checkpoint Inhibitors;
Immunosuppressive Agents/therapeutic use*;
Immunotherapy/methods*;
Ligands;
Lung Neoplasms/pathology*;
Programmed Cell Death 1 Receptor;
Tumor Microenvironment
- From:
Chinese Journal of Lung Cancer
2022;25(9):689-695
- CountryChina
- Language:Chinese
-
Abstract:
Cancer immunotherapy is increasingly popular in the field of cancer treatment, and related research is emerging. For patients with non-small cell lung cancer (NSCLC), in recent years, immune checkpoint inhibitors (ICIs) represented by programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) immunosuppressants, have become one of the most promising treatments for malignant tumors. Immune checkpoint blockade therapy includes anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) mAb, anti-PD-1 mAb and anti-PD-L1 mAb, with the best-known number of PD-L1 immunotherapy. At present, ICIs have achieved very good therapeutic results in clinical treatment, but with less effective efficiency, so we hope to obtain higher therapeutic efficiency. In recent years, exosomal PD-L1 has played an important role in the progress of immunotherapy for NSCLC. This paper reviews the effects of tumor exosomal PD-L1 protein on the tumor microenvironment, the effect prediction of immunotherapy, and as novel therapeutic strategies for immunotherapy in NSCLC.
.
